[Clinicopathological analysis of primary intestinal non-Hodgkin's lymphoma: a report of 32 cases]

Zhonghua Bing Li Xue Za Zhi. 2004 Oct;33(5):445-8.
[Article in Chinese]

Abstract

Objective: To investigate the clinical and pathological features and prognostic factors of primary intestinal non-Hodgkin's lymphoma (NHL).

Methods: Thirty-Two cases of intestinal NHL were studied clinically and pathologically. All cases were reclassified according to the WHO classification of lymphoma in 2001.

Results: Twenty-one cases (65.6%) were diagnosed as B-cell lymphomas, including 15 cases of diffuse large B-cell lymphoma, 2 cases of mantle cell lymphoma, 1 case of follicular lymphoma, 2 cases of MALT lymphoma and 1 case of Burkitt's lymphoma. Ten cases (31.2%) were diagnosed as T cell lymphomas, including 2 enteropathy-associated T cell lymphomas (EATCL) and 8 cases non-EATCL. One case (3.1%) was diagnosed as histiocytic lymphoma. Nine cases were at stage I-II and 23 cases were at stage III-IV. Follow-up information was available in all cases ranging from 4 to 168 months (mean 25.6 months). Fifteen cases died of the disease. The mortality rates were 33% for B cell lymphoma and 80% for T cell neoplasms. Based on Cox multivariate analysis, the clinical stage and histological types of the disease were important prognostic factors (P < 0.05). T cell lymphoma had a relatively poor prognosis.

Conclusions: Diffuse large B cell lymphoma is the most common subtype of primary intestinal lymphomas. Colon is the most common site involved, followed by the small intestine. Early stage of the disease and low-grade lymphoma appear to have a better prognosis. T cell lymphoma has a very poor prognosis.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Intestinal Neoplasms / pathology*
  • Intestinal Neoplasms / therapy
  • Lymphoma, B-Cell / pathology
  • Lymphoma, B-Cell / therapy
  • Lymphoma, Non-Hodgkin / pathology*
  • Lymphoma, Non-Hodgkin / therapy
  • Lymphoma, T-Cell / pathology
  • Lymphoma, T-Cell / therapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Survival Rate